Lumeva · MIG · Japan · Headache specialist · captured by Luis Ortega on 18 Apr 2026 · reviewed by Dr. Marcus Lindqvist on 24 Apr 2026
Verbatim as captured; never edited
Headache specialist at National Cancer Center Tokyo raised drug interactions during a scientific exchange. They asked whether additional data would be presented at the next congress.
Human-approved by Dr. Marcus Lindqvist on 24 Apr 2026
Drug interactions: practice variation observed reported by headache specialist (JP).
helixor-private-llm-2026.05 · generated 18 Apr 2026, 10:00 UTC
AI summary
Drug interactions raised by headache specialist; relevant for HEOR.
Source spans used by the model
Headache specialist at National Cancer Center Tokyo raised drug interactions during a scientific exchange. They asked whether additional data would be presented at the next congress.
| Field | AI suggestion | Final (human-approved) |
|---|---|---|
| Category | Adherence and persistence | Adherence and persistence |
| Function | HEOR | HEOR |
| Priority | Medium | Medium |
Transparent weighted model; contribution = value ÷ 5 × weight
| Dimension | Value (1–5) | Weight | Contribution |
|---|---|---|---|
| Patient relevance | 3 | 20% | 12.0 |
| Strategic alignment | 1 | 20% | 4.0 |
| Scientific importance | 3 | 15% | 9.0 |
| Urgency | 4 | 15% | 12.0 |
| Novelty | 4 | 10% | 8.0 |
| Actionability | 2 | 10% | 4.0 |
| Confidence | 5 | 5% | 5.0 |
| Breadth of occurrence | 1 | 5% | 1.0 |
| Total | Medium 55 | ||
No audit events in sample data
Every model call on this record and its human outcome
No AI interactions in sample data
Current stage and the next allowed action
Who reviewed, what action, which function, what decision, what outcome, when closed
17 Apr 2026 · Dr. Benedikt Castellano, National Cancer Center Tokyo · MSL Luis Ortega
Insight
Reviewed 24 Apr 2026 by Dr. Marcus Lindqvist
Action
Medical education program · Dr. Anna Becker · In progress
Decision
Outcome
Closure
Duplicate theme merged into strategic objective review.